PTEN loss correlates with the clinical efficacy of lapatinib in HER2 positive metastatic breast cancer with trastuzumab-resistance

National Medical Journal of China

Volumn 95, Issue 28, 2015, Pages 2264-2267

  Du, Ge ^a   Bian, Li ^a   Wang, Tao ^a   Xu, Xiaojie ^a   Zhang, Shaohua ^a   Guo, Yunfei ^a   Zhuo, Jinmei ^a   Song , Santai ^a   Jiang, Zefei ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Breast neoplasms; Drug resistance; Epidermal growth factor; Receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ARTICLE; BREAST METASTASIS; CLINICAL FEATURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROGRESSION FREE SURVIVAL; UNIVARIATE ANALYSIS; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG RESISTANCE; METASTASIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, ERBB-2; TRASTUZUMAB; TREATMENT OUTCOME;

EID: 84940670504     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2015.28.005     Document Type: Article

References (12)

1. Goldhirseh A, WinerEP, Coates AS, et al. Personalizing the treatment oi women with early breast cancer; highlights of the Si Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J]. Ann Oncol, 2013, 24(28 ) : 2206- 2223.
2. Vogel CI., Cobleigh MA, Tripatliv D, et al. Efficacy and safety of trastuznmah as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer[J]. J Clin Oncol, 2002, 20(3) : 719-726.
3. Marty M, Cognelti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positiye metastatic breast cancer administered as first-line treatment: The M77001 study group[J]. J Clin Oncol, 2005, 23 (19): 4265-4274.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. bse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2[J], N Engl J Med, 2001, 344 ( 11 ) : 783-792.
5. Nahta R, Yu D, Hung MC, et al. Mechanisms of disease; understanding resistance to HER2-targetedtherapy in human breast cancer [J], Nat Clin Praet Oncol, 2006, 3(5) : 269-280.
6. Geyer CE, Korster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [ J ] . N Engl J Med, 2006, 355(25) :2733-2743.
7. Bian L, Wang T, Jiang ZF, et al. Ki-67 index as a prognostic lactor of subsequent lapatinib-hased therapy in HER2-positive metastatic breast cancer yvith resistance to trastuzumab [ J ] . Cancer Biol Ther, 2014, 15(4) :365-370.
8. Bian L, Wang I, Zhang S, el al. Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer [ J ] . Tumour Biol, 2013, 34(5). 3153-3158.
9. Wang L, Zhang Q, Zhang J, et al. P13K pathway activation results in low efficacy of both trastuzumab and lapatinib [J]. BMC Cancer, 2011, 11(4); 248.
10. Eiehhorn PJ, Gill M, Scaltrili M, et al. Phosphalidylinositol 3- kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor WP-BEZ235 [ J]. Cancer Res, 2008, 68(22) : 9221-9230.
11. Xia W. Husain I, Liu L, et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers [ J]. Cancer Res, 2007, 67(3); 1170-1175.
12. Dave B, Migliaccio I, Gutierrez MC, et al. Loss ol phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers [ J]. J Clin Oncol, 2011, 29(2) : 166-173.